142 related articles for article (PubMed ID: 9607136)
1. Inhibition of isoproterenol-induced tachycardia by azimilide in the isolated perfused guinea pig heart.
Miller KE; Carpenter JF; Brooks RR
Cardiovasc Drugs Ther; 1998 Mar; 12(1):83-91. PubMed ID: 9607136
[TBL] [Abstract][Full Text] [Related]
2. Effects of azimilide and d,l-sotalol on the heart rate and blood pressure response to isoproterenol in anesthetized rats.
Mittelstadt SW; Maynard AE; Benn DR; Lowe ER; Kostreva DR
Cardiovasc Drugs Ther; 1997 Sep; 11(4):591-8. PubMed ID: 9358964
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of the class III antiarrhythmic agent azimilide in rodent models of ventricular arrhythmia.
Brooks RR; Carpenter JF; Miller KE; Maynard AE
Proc Soc Exp Biol Med; 1996 May; 212(1):84-93. PubMed ID: 8618956
[TBL] [Abstract][Full Text] [Related]
4. Suppression of inducible ventricular arrhythmias by intravenous azimilide in dogs with previous myocardial infarction.
Drexler AP; Micklas JM; Brooks RR
J Cardiovasc Pharmacol; 1996 Dec; 28(6):848-55. PubMed ID: 8961084
[TBL] [Abstract][Full Text] [Related]
5. Effects of the novel antiarrhythmic agent azimilide on experimental atrial fibrillation and atrial electrophysiologic properties.
Nattel S; Liu L; St-Georges D
Cardiovasc Res; 1998 Mar; 37(3):627-35. PubMed ID: 9659446
[TBL] [Abstract][Full Text] [Related]
6. Interaction of azimilide with neurohumoral and channel receptors.
Brooks RR; Pong SF; Izzo NJ; Moorehead TJ; Gopalakrishnan M; Triggle DJ
Biochem Pharmacol; 2001 Oct; 62(7):883-92. PubMed ID: 11543723
[TBL] [Abstract][Full Text] [Related]
7. The effect of isoproterenol on the class III effect of azimilide in humans.
Dorian P; Dunnmon P; Elstun L; Newman D
J Cardiovasc Pharmacol Ther; 2002 Oct; 7(4):211-7. PubMed ID: 12490966
[TBL] [Abstract][Full Text] [Related]
8. Azimilide dihydrochloride, a novel antiarrhythmic agent.
Karam R; Marcello S; Brooks RR; Corey AE; Moore A
Am J Cardiol; 1998 Mar; 81(6A):40D-46D. PubMed ID: 9537222
[TBL] [Abstract][Full Text] [Related]
9. Combined potassium and calcium channel antagonistic activities as a basis for neutral frequency dependent increase in action potential duration: comparison between BRL-32872 and azimilide.
Bril A; Forest MC; Cheval B; Faivre JF
Cardiovasc Res; 1998 Jan; 37(1):130-40. PubMed ID: 9539867
[TBL] [Abstract][Full Text] [Related]
10. Electrophysiological and antiarrhythmic effects of the novel I(Kur) channel blockers, S9947 and S20951, on left vs. right pig atrium in vivo in comparison with the I(Kr) blockers dofetilide, azimilide, d,l-sotalol and ibutilide.
Knobloch K; Brendel J; Peukert S; Rosenstein B; Busch AE; Wirth KJ
Naunyn Schmiedebergs Arch Pharmacol; 2002 Nov; 366(5):482-7. PubMed ID: 12382079
[TBL] [Abstract][Full Text] [Related]
11. Effects of azimilide on heart rate and ECG conduction intervals during sinus rhythm in patients with a history of atrial fibrillation.
Pritchett EL; Schulte MC; Schnell D; Marcello SR; Wilkinson WE; Page RL; Connolly SJ;
J Clin Pharmacol; 2002 Apr; 42(4):388-94. PubMed ID: 11936563
[TBL] [Abstract][Full Text] [Related]
12. Proarrhythmia of azimilide and other class III antiarrhythmic agents in the adrenergically stimulated rabbit.
Brooks RR; Drexler AP; Maynard AE; Al-Khalidi H; Kostreva DR
Proc Soc Exp Biol Med; 2000 Feb; 223(2):183-9. PubMed ID: 10654622
[TBL] [Abstract][Full Text] [Related]
13. Effects of intravenous azimilide on cardiac performance, fibrillation threshold, and hemodynamics in anesthetized dogs.
Brooks RR; Finch SL
Arzneimittelforschung; 2000 Jul; 50(7):597-605. PubMed ID: 10965415
[TBL] [Abstract][Full Text] [Related]
14. Phase 2 early afterdepolarization as a trigger of polymorphic ventricular tachycardia in acquired long-QT syndrome : direct evidence from intracellular recordings in the intact left ventricular wall.
Yan GX; Wu Y; Liu T; Wang J; Marinchak RA; Kowey PR
Circulation; 2001 Jun; 103(23):2851-6. PubMed ID: 11401944
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the rate-dependent properties of the class III antiarrhythmic agents azimilide (NE-10064) and E-4031: considerations on the mechanism of reverse rate-dependent action potential prolongation.
Groh WJ; Gibson KJ; Maylie JG
J Cardiovasc Electrophysiol; 1997 May; 8(5):529-36. PubMed ID: 9160229
[TBL] [Abstract][Full Text] [Related]
16. Pure class III agents for prevention of sudden cardiac death.
Pratt CM
J Cardiovasc Electrophysiol; 2003 Sep; 14(9 Suppl):S82-6. PubMed ID: 12950526
[TBL] [Abstract][Full Text] [Related]
17. Use-dependent effects of the class III antiarrhythmic agent NE-10064 (azimilide) on cardiac repolarization: block of delayed rectifier potassium and L-type calcium currents.
Fermini B; Jurkiewicz NK; Jow B; Guinosso PJ; Baskin EP; Lynch JJ; Salata JJ
J Cardiovasc Pharmacol; 1995 Aug; 26(2):259-71. PubMed ID: 7475051
[TBL] [Abstract][Full Text] [Related]
18. Azimilide dihydrochloride: a unique class III antiarrhythmic agent.
Tran HT
Heart Dis; 1999; 1(2):114-6. PubMed ID: 11720612
[TBL] [Abstract][Full Text] [Related]
19. The effect of high extracellular potassium on IKr inhibition by anti-arrhythmic agents.
Lin C; Ke X; Cvetanovic I; Ranade V; Somberg J
Cardiology; 2007; 108(1):18-27. PubMed ID: 16960444
[TBL] [Abstract][Full Text] [Related]
20. Azimilide (NE-10064) can prolong or shorten the action potential duration in canine ventricular myocytes: dependence on blockade of K, Ca, and Na channels.
Yao JA; Tseng GN
J Cardiovasc Electrophysiol; 1997 Feb; 8(2):184-98. PubMed ID: 9048249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
